Article(id=1326835819056312517, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326835704023330908, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.03.017, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1718035200000, receivedDateStr=2024-06-11, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794271910680, onlineDateStr=2026-11-10, pubDate=1741536000000, pubDateStr=2025-03-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794271910680, onlineIssueDateStr=2026-11-10, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794271910680, creator=13701087609, updateTime=1794271910680, updator=13701087609, issue=Issue{id=1326835704023330908, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='3', pageStart='211', pageEnd='314', issueExtLink='null', onlineDate='null', pubDate='1741536000000', pubDateStr='2025-03-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794271883254, creator='13701087609', updateTime=1794273076730, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840710357169115, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326835704023330908, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840710357169116, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326835704023330908, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=309, endPage=314, ext={EN=ArticleExt(id=1326835819228278982, articleId=1326835819056312517, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Research progress of melanotransferrin targeted antibody-drug conjugates in melanoma treatment, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Melanotransferrin(CD228) is a carboxy-terminal glycosyl-phosphatidylinositol anchored glycoprotein that plays a role in cell proliferation and tumorigenesis, angiogenesis, and iron transport and metabolism. Due to its heterogeneous expression in tumor cells, especially melanoma, and low expression in normal cells, CD228 is generally considered to be a specific target of antibody-drug conjugate(ADC). It is expected to provide a new treatment option for patients with advanced metastatic melanoma. This paper systematically reviewed the function of CD228, the basic principle of CD228 as an ADC target and its killing mechanism on tumors, the ADC drugs and their clinical application prospects of CD228 targeted therapy for melanoma, aiming to provide references for the development of CD228 targeted melanoma drugs.

, authors=Haitao QIU, Liping XIE*, authorsList=Haitao QIU, Liping XIE, authorCompany=null, correspAuthors=Liping XIE, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326835819517685959, articleId=1326835819056312517, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=黑素转铁蛋白靶向抗体偶联药物在黑色素瘤治疗中的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

黑素转铁蛋白(CD228)是一种羧基端糖基磷脂酰肌醇锚定糖蛋白,在细胞增殖和肿瘤发生、血管生成,以及铁转运和代谢过程中发挥作用。由于CD228在肿瘤细胞,尤其是黑色素瘤(melanoma)中异质表达、在正常细胞中低表达的特性,通常被认为是一个抗体偶联药物(antibody-drug conjugate,ADC)的特异性靶点,有望给晚期转移性黑色素瘤(advanced metastatic melanoma)患者提供一个新的治疗选择。该文系统综述CD228的功能、CD228作为ADC靶标的基本原理及其对肿瘤的杀伤机制,以及CD228靶向治疗黑色素瘤的ADC药物和临床应用前景,旨在为CD228靶向治疗黑色素瘤药物的开发提供参考。

, authors=邱海涛, 谢丽萍*, authorsList=邱海涛, 谢丽萍, authorCompany=null, correspAuthors=谢丽萍, authorNote=

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

, correspAuthorsNote=
谢丽萍,研究员,研究方向:生物大分子药物研发。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=vocknqhAZRaw771R1oif3A==, magXml=1RO7ulgbmmVm7feVtJN+dg==, pdfUrl=null, pdf=rnx8ryOXH3vJi2Lw1cd7Yw==, pdfFileSize=977344, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=FUijr5Gc8HQO7BYX4M3pSQ==, mapNumber=null, fund=null)}, authors=[Author(id=1326835821333819596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326835821459648718, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821333819596, language=EN, stringName=Haitao QIU, firstName=Haitao, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326835821526757583, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821333819596, language=CN, stringName=邱海涛, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

"}, bioImg=null, bioContent=

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326835821254127816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, xref=null, ext=[AuthorCompanyExt(id=1326835821262516425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326835821270905034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1326835821623226577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326835821702918355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821623226577, language=EN, stringName=Liping XIE, firstName=Liping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326835821774221524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821623226577, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326835821254127816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, xref=null, ext=[AuthorCompanyExt(id=1326835821262516425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326835821270905034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])], keywords=[Keyword(id=1326835821866496213, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=EN, orderNo=1, keyword=melanotransferrin), Keyword(id=1326835821925216470, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=EN, orderNo=2, keyword=antibody-drug conjugate), Keyword(id=1326835822009102551, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=EN, orderNo=3, keyword=melanoma), Keyword(id=1326835822084600024, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=EN, orderNo=4, keyword=targeted therapy), Keyword(id=1326835822147514585, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=CN, orderNo=1, keyword=黑素转铁蛋白), Keyword(id=1326835822206234842, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=CN, orderNo=2, keyword=抗体偶联药物), Keyword(id=1326835822264955099, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=CN, orderNo=3, keyword=黑色素瘤), Keyword(id=1326835822319481052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, language=CN, orderNo=4, keyword=靶向治疗)], refs=[Reference(id=1326835822407561437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=SAGINALA K, BARSOUK A, ALURU JS, et al.Epidemiology of melanoma[J]. Med Sci(Basel), 2021, 9(4):63., articleTitle=null, refAbstract=null), Reference(id=1326835822491447518, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=BONHOURE A, HENRY L, MORILLE M, et al. Exosomal melanotransferrin as a potential biomarker for metastatic melanoma[J]. bioRxiv, 2020, 11: 373852., articleTitle=null, refAbstract=null), Reference(id=1326835822554362079, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SURYO RAHMANTO Y, BAL S, LOH KH, et al. Melanotransferrin: search for a function[J]. Biochim Biophys Acta, 2012, 1820(3): 237-243., articleTitle=null, refAbstract=null), Reference(id=1326835822613082336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=DUBON M, LEE S, PARK JH, et al. The role of melanotransferrin(CD228) in the regulation of the differentiation of human bone marrow-derived mesenchymal stem cells(hBM-MSC)[J]. Int J Med Sci, 2021, 18(7):1580-1591., articleTitle=null, refAbstract=null), Reference(id=1326835822667608289, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=ABDOLLAHPOUR-ALITAPPEH M, LOTFINIA M,GHARIBI T, et al. Antibody-drug conjugates(ADCs) for cancer therapy: strategies, challenges, and successes[J]. J Cell Physiol, 2019, 234(5): 5628-5642., articleTitle=null, refAbstract=null), Reference(id=1326835822726328546, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=FU Z, LI S, HAN S, et al. Antibody drug conjugate: the''biological missile'' for targeted cancer therapy[J]. Signal Transduct Target Ther, 2022, 7(1): 93., articleTitle=null, refAbstract=null), Reference(id=1326835822797631715, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=KHONGORZUL P, LING CJ, KHAN FU, et al. Antibody-drug conjugates: a comprehensive review[J]. Mol Cancer Res, 2020, 18(1): 3-19., articleTitle=null, refAbstract=null), Reference(id=1326835822881517796, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=DRAGO JZ, MODI S, CHANDARLAPATY S. Unlocking the potential of antibody-drug conjugates for cancer therapy[J].Nat Rev Clin Oncol, 2021, 18(6): 327-344., articleTitle=null, refAbstract=null), Reference(id=1326835822948626661, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=LEI Y, LU Z, HUANG J, et al. The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer[J]. Cell Death Dis, 2020, 11(10): 933., articleTitle=null, refAbstract=null), Reference(id=1326835823015735526, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=JANDOVA J, WONDRAK GT. Melanotransferrin(MELTF,CD228) as a determinant of melanomagenesis: MELTF expression attenuates melanoma progression in the A375-luc2 murine metastasis model and human patients[J]. J Invest Dermatol, 2024, 144(12): 2820-2823., articleTitle=null, refAbstract=null), Reference(id=1326835823095427303, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=ASHRAF A, ALEPUZ GUILLEN JA, ALJUHANI M, et al. Low cerebrospinal fluid levels of melanotransferrin are associated with conversion of mild cognitively impaired subjects to Alzheimer's disease[J]. Front Neurosci, 2019, 13:181., articleTitle=null, refAbstract=null), Reference(id=1326835823162536168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=PALUNCIC J, GHOLAM AZAD M, LANE DJR, et al.Melanotransferrin functions as a pro-oncogenic WNT agonist: a Yin-Yang relationship in melanoma with the WNT antagonist and metastasis suppressor, NDRG1[J]. bioRxiv,2023, 2: 530353., articleTitle=null, refAbstract=null), Reference(id=1326835823242227945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=CHHABRA G, AHMAD N. Mystery of melanotransferrin in melanoma[J]. J Invest Dermatol, 2024, 144(12): 2619-2622., articleTitle=null, refAbstract=null), Reference(id=1326835823317725418, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=RICHARDSON DR. The role of the membrane‐bound tumour antigen, melanotransferrin(p97), in iron uptake by the human malignant melanoma cell[J]. Eur J Biochem, 2000, 267(5):1290-1298., articleTitle=null, refAbstract=null), Reference(id=1326835823397417195, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=ANDREASEN PA, KJOLLER L, CHRISTENSEN L, et al.The urokinase‐type plasminogen activator system in cancer metastasis: a review[J]. Int J Cancer, 1997, 72(1): 1-22., articleTitle=null, refAbstract=null), Reference(id=1326835823472914668, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=BONHOURE A, HENRY L, MORILLE M, et al.Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells[J]. Melanoma Res,2021, 31(4): 338-351., articleTitle=null, refAbstract=null), Reference(id=1326835823535829229, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=MICHAUD-LEVESQUE J, DEMEULE M, BELIVEAU R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin[J]. Carcinogenesis, 2007, 28(2): 280-288., articleTitle=null, refAbstract=null), Reference(id=1326835823607132398, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=JAKARIA M, BELAIDI AA, BUSH AI, et al. Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease[J].J Neurochem, 2021, 159(5): 804-825., articleTitle=null, refAbstract=null), Reference(id=1326835823724572911, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=CRISCITIELLO C, MORGANTI S, CURIGLIANO G.Antibody-drug conjugates in solid tumors: a look into novel targets[J]. J Hematol Oncol, 2021, 14(1): 20., articleTitle=null, refAbstract=null), Reference(id=1326835823854596336, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=JIN Y, SCHLADETSCH MA, HUANG X, et al. Stepping forward in antibody-drug conjugate development[J].Pharmacol Ther, 2022, 229: 107917., articleTitle=null, refAbstract=null), Reference(id=1326835823921705201, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=MAZAHREH R, MASON ML, GOSINK JJ, et al. SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models[J]. Mol Cancer Ther, 2023, 22(4): 421-434., articleTitle=null, refAbstract=null), Reference(id=1326835825607815411, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH LM, NESTEROVA A, ALLEY SC, et al.Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97[J]. Mol Cancer Ther, 2006, 5(6):1474-1482., articleTitle=null, refAbstract=null), Reference(id=1326835825683312884, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=MAREI HE, CENCIARELLI C, HASAN A. Potential of antibody-drug conjugates(ADCs) for cancer therapy[J].Cancer Cell Int, 2022, 22(1): 255., articleTitle=null, refAbstract=null), Reference(id=1326835825746227445, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=SIMON L, CAMPOS A, LEYTON L, et al. Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer[J]. Cancer Metastasis Rev, 2020,39(2): 435-453., articleTitle=null, refAbstract=null), Reference(id=1326835825821724918, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=GIUGLIANO F, CORTI C, TARANTINO P, et al. Bystander effect of antibody-drug conjugates: fact or fiction[J]. Curr Oncol Rep, 2022, 24(7): 809-817., articleTitle=null, refAbstract=null), Reference(id=1326835825905610999, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=PINTO S, PAHL J, SCHOTTELIUS A, et al. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers[J]. Trends in Immunol, 2022, 43(11): 932-946., articleTitle=null, refAbstract=null), Reference(id=1326835825976914168, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDALL SL, MASON M, OLSON D, et al. SGN-CD228A: a novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors[J]. Cancer Res,2019, 79(13_Supplement): 2688., articleTitle=null, refAbstract=null), Reference(id=1326835826044023033, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDALL S, MAZAHREH R, MASON M, et al. Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate(ADC) for solid tumors[J]. Cancer Res, 2020, 80(16_Supplement):2888., articleTitle=null, refAbstract=null), Reference(id=1326835826127909114, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=山东博安生物技术股份有限公司. 抗CD228抗体及其药物偶联物: 中国, WO2023231877A1[P]. 2023-12-07., articleTitle=null, refAbstract=null), Reference(id=1326835826199212283, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=PRAMANIK D. Development of antibody-drug conjugates:future perspective towards solid tumor treatment[J].Anticancer Agents Med Chem, 2023, 23(6): 642-657., articleTitle=null, refAbstract=null), Reference(id=1326835826270515452, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=SIEMERS NO, KERR DE, YARNOLD S, et al. Construction,expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation[J]. Bioconjug Chem, 1997, 8(4): 510-519., articleTitle=null, refAbstract=null), Reference(id=1326835826350207229, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=LIN Q, WANG X, HU Y. The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells[J]. Cancer Lett, 2023, 10: 216318., articleTitle=null, refAbstract=null), Reference(id=1326835826413121790, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=PANG K, SHI ZD, WEI LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade[J]. Drug Resist Updat,2023, 66: 100907., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326835821254127816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, xref=null, ext=[AuthorCompanyExt(id=1326835821262516425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326835821270905034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.03.017, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.03.017, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.03.017, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.03.017, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1741536000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
黑素转铁蛋白靶向抗体偶联药物在黑色素瘤治疗中的研究进展
邱海涛 , 谢丽萍 *
世界临床药物 | 综述评论 2025,46(3): 309-314
收起
收藏切换
世界临床药物 |综述评论 2025 , 46 (3) : 309 -314
黑素转铁蛋白靶向抗体偶联药物在黑色素瘤治疗中的研究进展
全屏
[Author(id=1326835821333819596, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326835821459648718, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821333819596, language=EN, stringName=Haitao QIU, firstName=Haitao, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326835821526757583, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821333819596, language=CN, stringName=邱海涛, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院,上海 201203, bio={"content":"

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

"}, bioImg=null, bioContent=

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326835821254127816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, xref=null, ext=[AuthorCompanyExt(id=1326835821262516425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326835821270905034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])]), Author(id=1326835821623226577, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326835821702918355, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821623226577, language=EN, stringName=Liping XIE, firstName=Liping, middleName=null, lastName=XIE, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326835821774221524, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, authorId=1326835821623226577, language=CN, stringName=谢丽萍, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326835821254127816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, xref=null, ext=[AuthorCompanyExt(id=1326835821262516425, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326835821270905034, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326835819056312517, companyId=1326835821254127816, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院,上海 201203)])])]
邱海涛, 谢丽萍*
作者信息
  • 中国医药工业研究总院,上海 201203
通讯作者:
谢丽萍,研究员,研究方向:生物大分子药物研发。
作者简介:

邱海涛,硕士研究生,研究方向:生物大分子药物研发。

Research progress of melanotransferrin targeted antibody-drug conjugates in melanoma treatment
Haitao QIU, Liping XIE*
Affiliations
  • China State Institute of Pharmaceutical Industry, Shanghai 201203, China
出版时间: 2025-03-10 doi: 10.13683/j.wph.2025.03.017
文章导航
收藏切换

黑素转铁蛋白(CD228)是一种羧基端糖基磷脂酰肌醇锚定糖蛋白,在细胞增殖和肿瘤发生、血管生成,以及铁转运和代谢过程中发挥作用。由于CD228在肿瘤细胞,尤其是黑色素瘤(melanoma)中异质表达、在正常细胞中低表达的特性,通常被认为是一个抗体偶联药物(antibody-drug conjugate,ADC)的特异性靶点,有望给晚期转移性黑色素瘤(advanced metastatic melanoma)患者提供一个新的治疗选择。该文系统综述CD228的功能、CD228作为ADC靶标的基本原理及其对肿瘤的杀伤机制,以及CD228靶向治疗黑色素瘤的ADC药物和临床应用前景,旨在为CD228靶向治疗黑色素瘤药物的开发提供参考。

黑素转铁蛋白  /  抗体偶联药物  /  黑色素瘤  /  靶向治疗

Melanotransferrin(CD228) is a carboxy-terminal glycosyl-phosphatidylinositol anchored glycoprotein that plays a role in cell proliferation and tumorigenesis, angiogenesis, and iron transport and metabolism. Due to its heterogeneous expression in tumor cells, especially melanoma, and low expression in normal cells, CD228 is generally considered to be a specific target of antibody-drug conjugate(ADC). It is expected to provide a new treatment option for patients with advanced metastatic melanoma. This paper systematically reviewed the function of CD228, the basic principle of CD228 as an ADC target and its killing mechanism on tumors, the ADC drugs and their clinical application prospects of CD228 targeted therapy for melanoma, aiming to provide references for the development of CD228 targeted melanoma drugs.

melanotransferrin  /  antibody-drug conjugate  /  melanoma  /  targeted therapy
邱海涛, 谢丽萍. 黑素转铁蛋白靶向抗体偶联药物在黑色素瘤治疗中的研究进展. 世界临床药物, 2025 , 46 (3) : 309 -314 . DOI: 10.13683/j.wph.2025.03.017
Haitao QIU, Liping XIE. Research progress of melanotransferrin targeted antibody-drug conjugates in melanoma treatment[J]. World Clinical Drug, 2025 , 46 (3) : 309 -314 . DOI: 10.13683/j.wph.2025.03.017

参考文献 引证文献
排序方式:
[1]
SAGINALA K, BARSOUK A, ALURU JS, et al.Epidemiology of melanoma[J]. Med Sci(Basel), 2021, 9(4):63.
[2]
BONHOURE A, HENRY L, MORILLE M, et al. Exosomal melanotransferrin as a potential biomarker for metastatic melanoma[J]. bioRxiv, 2020, 11: 373852.
[3]
SURYO RAHMANTO Y, BAL S, LOH KH, et al. Melanotransferrin: search for a function[J]. Biochim Biophys Acta, 2012, 1820(3): 237-243.
[4]
DUBON M, LEE S, PARK JH, et al. The role of melanotransferrin(CD228) in the regulation of the differentiation of human bone marrow-derived mesenchymal stem cells(hBM-MSC)[J]. Int J Med Sci, 2021, 18(7):1580-1591.
[5]
ABDOLLAHPOUR-ALITAPPEH M, LOTFINIA M,GHARIBI T, et al. Antibody-drug conjugates(ADCs) for cancer therapy: strategies, challenges, and successes[J]. J Cell Physiol, 2019, 234(5): 5628-5642.
[6]
FU Z, LI S, HAN S, et al. Antibody drug conjugate: the''biological missile'' for targeted cancer therapy[J]. Signal Transduct Target Ther, 2022, 7(1): 93.
[7]
KHONGORZUL P, LING CJ, KHAN FU, et al. Antibody-drug conjugates: a comprehensive review[J]. Mol Cancer Res, 2020, 18(1): 3-19.
[8]
DRAGO JZ, MODI S, CHANDARLAPATY S. Unlocking the potential of antibody-drug conjugates for cancer therapy[J].Nat Rev Clin Oncol, 2021, 18(6): 327-344.
[9]
LEI Y, LU Z, HUANG J, et al. The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer[J]. Cell Death Dis, 2020, 11(10): 933.
[10]
JANDOVA J, WONDRAK GT. Melanotransferrin(MELTF,CD228) as a determinant of melanomagenesis: MELTF expression attenuates melanoma progression in the A375-luc2 murine metastasis model and human patients[J]. J Invest Dermatol, 2024, 144(12): 2820-2823.
[11]
ASHRAF A, ALEPUZ GUILLEN JA, ALJUHANI M, et al. Low cerebrospinal fluid levels of melanotransferrin are associated with conversion of mild cognitively impaired subjects to Alzheimer's disease[J]. Front Neurosci, 2019, 13:181.
[12]
PALUNCIC J, GHOLAM AZAD M, LANE DJR, et al.Melanotransferrin functions as a pro-oncogenic WNT agonist: a Yin-Yang relationship in melanoma with the WNT antagonist and metastasis suppressor, NDRG1[J]. bioRxiv,2023, 2: 530353.
[13]
CHHABRA G, AHMAD N. Mystery of melanotransferrin in melanoma[J]. J Invest Dermatol, 2024, 144(12): 2619-2622.
[14]
RICHARDSON DR. The role of the membrane‐bound tumour antigen, melanotransferrin(p97), in iron uptake by the human malignant melanoma cell[J]. Eur J Biochem, 2000, 267(5):1290-1298.
[15]
ANDREASEN PA, KJOLLER L, CHRISTENSEN L, et al.The urokinase‐type plasminogen activator system in cancer metastasis: a review[J]. Int J Cancer, 1997, 72(1): 1-22.
[16]
BONHOURE A, HENRY L, MORILLE M, et al.Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma cells[J]. Melanoma Res,2021, 31(4): 338-351.
[17]
MICHAUD-LEVESQUE J, DEMEULE M, BELIVEAU R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin[J]. Carcinogenesis, 2007, 28(2): 280-288.
[18]
JAKARIA M, BELAIDI AA, BUSH AI, et al. Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease[J].J Neurochem, 2021, 159(5): 804-825.
[19]
CRISCITIELLO C, MORGANTI S, CURIGLIANO G.Antibody-drug conjugates in solid tumors: a look into novel targets[J]. J Hematol Oncol, 2021, 14(1): 20.
[20]
JIN Y, SCHLADETSCH MA, HUANG X, et al. Stepping forward in antibody-drug conjugate development[J].Pharmacol Ther, 2022, 229: 107917.
[21]
MAZAHREH R, MASON ML, GOSINK JJ, et al. SGN-CD228A is an investigational CD228-directed antibody-drug conjugate with potent antitumor activity across a wide spectrum of preclinical solid tumor models[J]. Mol Cancer Ther, 2023, 22(4): 421-434.
[22]
SMITH LM, NESTEROVA A, ALLEY SC, et al.Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97[J]. Mol Cancer Ther, 2006, 5(6):1474-1482.
[23]
MAREI HE, CENCIARELLI C, HASAN A. Potential of antibody-drug conjugates(ADCs) for cancer therapy[J].Cancer Cell Int, 2022, 22(1): 255.
[24]
SIMON L, CAMPOS A, LEYTON L, et al. Caveolin-1 function at the plasma membrane and in intracellular compartments in cancer[J]. Cancer Metastasis Rev, 2020,39(2): 435-453.
[25]
GIUGLIANO F, CORTI C, TARANTINO P, et al. Bystander effect of antibody-drug conjugates: fact or fiction[J]. Curr Oncol Rep, 2022, 24(7): 809-817.
[26]
PINTO S, PAHL J, SCHOTTELIUS A, et al. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers[J]. Trends in Immunol, 2022, 43(11): 932-946.
[27]
SANDALL SL, MASON M, OLSON D, et al. SGN-CD228A: a novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors[J]. Cancer Res,2019, 79(13_Supplement): 2688.
[28]
SANDALL S, MAZAHREH R, MASON M, et al. Utilizing PDX models to better understand factors that predict response to SGN-CD228A, an antibody drug-conjugate(ADC) for solid tumors[J]. Cancer Res, 2020, 80(16_Supplement):2888.
[29]
山东博安生物技术股份有限公司. 抗CD228抗体及其药物偶联物: 中国, WO2023231877A1[P]. 2023-12-07.
[30]
PRAMANIK D. Development of antibody-drug conjugates:future perspective towards solid tumor treatment[J].Anticancer Agents Med Chem, 2023, 23(6): 642-657.
[31]
SIEMERS NO, KERR DE, YARNOLD S, et al. Construction,expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation[J]. Bioconjug Chem, 1997, 8(4): 510-519.
[32]
LIN Q, WANG X, HU Y. The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells[J]. Cancer Lett, 2023, 10: 216318.
[33]
PANG K, SHI ZD, WEI LY, et al. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade[J]. Drug Resist Updat,2023, 66: 100907.
2025年第46卷第3期
48
10
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.03.017
  • 接收时间:2024-06-11
  • 首发时间:2026-11-10
  • 出版时间:2025-03-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-06-11
基金
作者信息
    中国医药工业研究总院,上海 201203

通讯作者:

谢丽萍,研究员,研究方向:生物大分子药物研发。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.03.017
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏